Get started
Author

Catherine Dutreix

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
2010 · Thomas Fischer, Richard M. Stone, et al. · Journal of Clinical Oncology · 515
PDF
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
2012 · R M Stone, T Fischer, et al. · Leukemia · 275
Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C
2001 · D. J. Propper, A. C. McDonald, et al. · Journal of Clinical Oncology · 234
Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion
2004 · Bin Peng, Catherine Dutreix, et al. · The Journal of Clinical Pharmacology · 166
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia
2003 · S G O'Brien, P Meinhardt, et al. · British Journal of Cancer · 159
PDF
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
2004 · Catherine Dutreix, Bin Peng, et al. · Cancer Chemotherapy and Pharmacology · 157
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial
2017 · D J DeAngelo, T I George, et al. · Leukemia · 152
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
2009 · M Campone, V Levy, et al. · British Journal of Cancer · 99
PDF
Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
2013 · Catherine Dutreix, Florence Munarini, et al. · Cancer Chemotherapy and Pharmacology · 92
PDF
Preclinical and Phase I Results of Decitabine in Combination with Midostaurin ( PKC 412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia
2013 · Casey B. Williams, Suman Kambhampati, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 68
Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth
2015 · B Peter, G E Winter, et al. · Leukemia · 65
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug–drug interaction study between midostaurin and rifampicin
2014 · Catherine Dutreix, Sebastien Lorenzo, et al. · European Journal of Clinical Pharmacology · 59
PDF
Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia
2008 · Yanfeng Wang, Li Zhou, et al. · British Journal of Clinical Pharmacology · 55
PDF
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer
2006 · Herlinde Dumez, Helen Gall, et al. · Anti-Cancer Drugs · 53
KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial
2010 · Jason Gotlib, Daniel J. DeAngelo, et al. · Blood · 52
Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen
2008 · Renzo Galanello, Antonio Piga, et al. · The Journal of Clinical Pharmacology · 44
A phase 1/2, open‐label, dose‐escalation study of midostaurin in children with relapsed or refractory acute leukaemia
2018 · C. Michel Zwaan, Stefan Söderhäll, et al. · British Journal of Haematology · 38
PDF
A Phase 1b Study of Midostaurin (PKC412) in Combination with Daunorubicin and Cytarabine Induction and High-Dose Cytarabine Consolidation in Patients Under Age 61 with Newly Diagnosed De Novo Acute Myeloid Leukemia: Overall Survival of Patients Whose Blasts Have FLT3 Mutations Is Similar to Those with Wild-Type FLT3.
2009 · Richard M Stone, Thomas Fischer, et al. · Blood · 37
Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin
2017 · Helen Gu, Catherine Dutreix, et al. · Drug Metabolism and Disposition · 36
PDF
Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia
2007 · Alan V. Boddy, Julieann Sludden, et al. · Clinical Cancer Research · 34
PDF
New insights on SOM230, a universal somatostatin receptor ligand.
2003 · V Boerlin, J van der Hoek, et al. · PubMed · 34
Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers
2012 · Adam del Corral, Catherine Dutreix, et al. · Cancer Chemotherapy and Pharmacology · 21
PDF
Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks
2008 · R. Séchaud, C. Dutreix, et al. · International Journal of Clinical Pharmacology and Therapeutics · 20
Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials
2025 · Ana de Vera, Paula R Clemens, et al. · Steroids · 11
A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)
2015 · C. Michel Zwaan, Stefan Söderhäll, et al. · Blood · 9
Works count: 39
Citation count: 2,500
H-index: 21
I10-index: 24
Year
Topic
Type